{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:50:33Z","timestamp":1782172233006,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Institute of Psychiatry and Neurology","award":["501-04-16-045"],"award-info":[{"award-number":["501-04-16-045"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clinbiochem.2019.09.009","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T12:09:50Z","timestamp":1572264590000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Comparison of plasma, saliva, and hair lamotrigine concentrations"],"prefix":"10.1016","volume":"74","author":[{"given":"Julita","family":"Kuczynska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Karas-Ruszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Zakrzewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Dermanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halina","family":"Sienkiewicz-Jarosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Kurkowska-Jastrzebska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Bienkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Konopko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Dominiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Mierzejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.clinbiochem.2019.09.009_b0005","first-page":"S30","article-title":"Lamotrigine","volume":"40","author":"Matsuo","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0010","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/070674370104600403","article-title":"Lamotrigine: a review of clinical studies in bipolar disorders","volume":"46","author":"Zerjav-Lacombe","year":"2001","journal-title":"Can. J. Psychiatry."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0015","article-title":"Lamotrigine for acute and chronic pain","volume":"CD006044","author":"Wiffen","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fphar.2015.00242","article-title":"Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer","volume":"6","author":"Prabhavalkar","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0025","first-page":"80","article-title":"Carbamazepine and lamotrigine plasma concentrations in epileptic patients during optimising therapy","volume":"64","author":"Krasniqi","year":"2010","journal-title":"Med. Arh."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1055\/s-2007-979570","article-title":"Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder","volume":"29","author":"Walden","year":"1996","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0035","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.WNL.0000138424.33979.0C","article-title":"Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy","volume":"63","author":"Hirsch","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0920-1211(90)90077-9","article-title":"A randomized double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy","volume":"6","author":"Sander","year":"1990","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.59.2.251","article-title":"Lamotrigine clearance during pregnancy","volume":"59","author":"Tran","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0050","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1212\/01.WNL.0000076485.09353.7A","article-title":"Oral contraceptives reduce lamotrigine plasma levels","volume":"61","author":"Sabers","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0920-1211(89)90007-7","article-title":"Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy","volume":"4","author":"Binnie","year":"1989","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0060","first-page":"517","article-title":"Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers","volume":"57","author":"Incecayir","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0065","first-page":"599","article-title":"A sensitive and selective HPLC method for estimation of lamotrigine in human plasma and saliva: application to plasma-saliva correlation in epileptic patients","volume":"60","author":"Mallayasamy","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0070","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jocn.2005.12.037","article-title":"Monitoring salivary lamotrigine concentrations","volume":"13","author":"Malone","year":"2006","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FTD.0b013e31827c11e7","article-title":"Therapeutic drug monitoring of antiepileptic drugs by use of saliva","volume":"35","author":"Patsalos","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0080","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1592\/phco.23.15.1550.31957","article-title":"Correlation of lamotrigine concentrations between serum and saliva","volume":"23","author":"Ryan","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0085","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00007691-200010000-00003","article-title":"Saliva and serum concentration of lamotrigine in patients with epilepsy","volume":"22","author":"Tsiropoulos","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0090","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1528-1157.2002.38601.x","article-title":"Self-discontinuation of antiepileptic medication in pregnancy: detection by hair analysis","volume":"43","author":"Williams","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/FTD.0000000000000396","article-title":"Comparison of plasma, saliva, and hair levetiracetam concentrations","volume":"39","author":"Kara\u015b-Ruszczyk","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00228-016-2163-5","article-title":"Monitoring of adherence to headache treatments by means of hair analysis","volume":"73","author":"Ferrari","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.forsciint.2004.04.022","article-title":"Recommendations for hair testing in forensic cases","volume":"145","author":"Society of Hair Testing","year":"2004","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0110","unstructured":"World Health Organization (2004). ICD-10: International Statistical Classification of Diseases and Related Health Problems: tenth revision, second ed. World Health Organization. https:\/\/apps.who.int\/iris\/handle\/10665\/42980."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med. Care."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0120","series-title":"Principles of Good Laboratory Practice (As Revised in 1997), Series on Principles of Good Laboratory Practice and Compliance Monitoring, No 1, OECD, ENV\/MC\/CHEM\/(98) 17","author":"Organisation for Economic Cooperation and Development","year":"1998"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0125","series-title":"Guideline on Bioanalytical Method Validation EMEA\/CHMP\/EWP\/192217\/2009","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/2045125316672573","article-title":"Variation in dose and plasma level of lamotrigine in patients discharged from a mental health trust","volume":"7","author":"Douglas-Hall","year":"2017","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":"Therapeutic drug monitoring of the newer antiepileptic drugs","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0140","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1528-1157.1996.tb00605.x","article-title":"Concentration\u2013effect and concentration-toxicity relations with lamotrigine: a prospective study","volume":"37","author":"Kilpatrick","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0145","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061909","article-title":"Therapeutic drug monitoring of the newer anti-epilepsy medications","volume":"3","author":"Krasowski","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0150","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1528-1157.2003.46902.x","article-title":"Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units","volume":"44","author":"Lardizabal","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0155","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2125.1998.00835.x","article-title":"Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service","volume":"46","author":"Morris","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.clinbiochem.2019.09.009_b0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0379-0738(93)90279-J","article-title":"Utilization of hair analysis for therapeutic drug monitoring with a special reference to ofloxacin and to nicotine","volume":"63","author":"Uematsu","year":"1993","journal-title":"Forensic. Sci. Int."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0165","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0379-0738(94)01619-G","article-title":"Phenobarbital in hair and drug monitoring","volume":"70","author":"Goulle","year":"1995","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0170","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/096032719501401006","article-title":"Testing human hair for carbamazepine in epileptic patients: is hair investigation suitable for drug monitoring?","volume":"14","author":"Kintz","year":"1995","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0175","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00007691-199702000-00017","article-title":"Simultaneous determination of phenytoin and carbamazepine in human hair by high-performance liquid chromatography","volume":"19","author":"Mei","year":"1997","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00007691-200102000-00004","article-title":"Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population","volume":"23","author":"Williams","year":"2001","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0185","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.56.5.448","article-title":"Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures","volume":"56","author":"Schapel","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0190","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0920-1211(90)90099-H","article-title":"A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures","volume":"7","author":"Loiseau","year":"1990","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0195","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0920-1211(95)00085-2","article-title":"A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy","volume":"23","author":"Reunanen","year":"1996","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1528-1157.1994.tb02920.x","article-title":"Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial","volume":"35","author":"Messenheimer","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0205","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1528-1157.1993.tb02417.x","article-title":"Outcomes of add-on treatment with lamotrigine in partial epilepsy","volume":"34","author":"Smith","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0210","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1528-1157.1989.tb05309.x","article-title":"Controlled trial of lamotrigine (Lamictal) for refractory partial seizures","volume":"30","author":"Jawad","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0215","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0220","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?","volume":"45","author":"Johannessen","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0225","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1212\/01.wnl.0000289511.20864.2a","article-title":"Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency","volume":"70","author":"Pennell","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0230","first-page":"15","article-title":"The relevance of monitoring lamotrigine serum concentrations in chronic pain patients","volume":"206","author":"Devulder","year":"2006","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.clinbiochem.2019.09.009_b0235","first-page":"211","article-title":"Pharmacokinetics of lamotrigine (Lamictal) in plasma and saliva","volume":"3","author":"Trnavska","year":"1991","journal-title":"Eur. J. Drug Metab. Pharmacokinet."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912019306952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912019306952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:09:52Z","timestamp":1762114192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912019306952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":47,"alternative-id":["S0009912019306952"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.09.009","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of plasma, saliva, and hair lamotrigine concentrations","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}